AstraZeneca extends its investment in Russia
- Details
- Category: AstraZeneca
AstraZeneca announced today that it plans to establish a Predictive Science Centre in St. Petersburg over the coming year. The move strengthens AstraZeneca's investments in Russia and supports the Russian Government's strategy to modernise and develop the country's pharmaceutical sector.
Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets
- Details
- Category: Nycomed
Nycomed has completed the transfer of marketing authorisation approvals in a number of key Asia-Pacific markets for osteoporosis treatment Bonviva (Ibandronate). The licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) marks a further strengthening of Nycomed's bone health franchise in the region.
GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) has entered into an agreement to acquire the remaining 51% equity interest of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd (Neptunus) in the joint venture (JV) company, Shenzhen GSK-Neptunus Biologicals Co. Ltd. (GSKNB), for a total cash consideration of£24 million (US$39 million).
Synthes and Lilly Sign Development and Collaboration Agreement
- Details
- Category: Eli Lilly and Company
Synthes, Inc. (SIX: SYST.VX) and Eli Lilly and Company (NYSE: LLY) announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic surgeons, including those with osteoporosis and those with bone fractures.
GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga™ (ezogabine) Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.
Abbott Reports Interim Results From Phase III Open-Label Study of Investigational Treatment for Advanced Parkinson's Disease
- Details
- Category: Abbott
Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias.
Millions of children in the world's poorest countries could receive vaccination against rotavirus diarrhoeal disease
- Details
- Category: GlaxoSmithKline
GSK announced that it has made a new offer to supplyits rotavirus vaccine, RotarixTM, to the GAVI Alliance at $2.50 per dose, a small fraction of developed world prices.
More Pharma News ...
- Pfizer Conducts First "Virtual" Clinical Trial Allowing Patients to Participate Regardless of Geography
- Novartis drug Glivec® shows significant overall survival benefit
- Pfizer and Hisun Sign MOU to Establish a Joint Venture
- Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement
- Novartis highlights extensive data on numerous compounds at ASCO
- AstraZeneca and Heptares collaborate to investigate important GPCR drug targets
- Sanofi and DNDi - Drugs for Neglected Diseases initiative - Sign an Innovative Agreement